AOCI at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s AOCI?
- Spyre Therapeutics, Inc. (SYRE) reported AOCI of -$767K in Q1 2026.
- How has Spyre Therapeutics, Inc.'s AOCI changed year-over-year?
- Spyre Therapeutics, Inc.'s AOCI decreased by 212.5% year-over-year, from $682K to -$767K.
- What is the long-term trend for Spyre Therapeutics, Inc.'s AOCI?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s AOCI has grown at a 139.6% compound annual growth rate (CAGR), from $11K to $869K.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.